ARTICLE | Emerging Company Profile
Crescendo: Best of Both Fragments
Crescendo's mouse creates human antibody fragments with in vivo maturation
May 17, 2010 7:00 AM UTC
Crescendo Biologics Ltd. believes its transgenic mouse antibody fragment technology combines the best characteristics of the two leading antibody fragment platforms - human origin and in vivomaturation - which should allow rapid creation of high affinity fragments. The company hopes to have clinical proof of concept (POC) in about three years.
"The core advantage of our Crescendo mouse over domain antibodies or Nanobodies is that it's human and it's matured in vivo, with all the advantages that gives in terms of maturation to high affinity and good solubility properties," founder and CSO Mike Romanos told BioCentury...